<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02111499</url>
  </required_header>
  <id_info>
    <org_study_id>H553000-1308</org_study_id>
    <secondary_id>2013-003754-24</secondary_id>
    <nct_id>NCT02111499</nct_id>
  </id_info>
  <brief_title>Efficacy, Tolerability and Safety of LAS41004 Formulations in a Psoriasis Plaque Test</brief_title>
  <official_title>A Randomized, Controlled, Observer-blind Psoriasis Plaque Test to Investigate the Anti-psoriatic Efficacy, Tolerability and Safety (Skin Atrophy) of LAS41004 Formulations in Patients With Mild to Moderate Plaque Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Almirall, S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>proDERM GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Almirall, S.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Clinical investigation of anti-psoriatic efficacy and atrophy
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this trial three concentrations of bexarotene in combination with a fixed concentration of
      betamethasone dipropionate, as well as monotherapy with bexarotene, will be investigated
      regarding their efficacy, tolerability and safety in patients with mild to moderate plaque
      psoriasis and will be compared with the vehicle and an active comparator.

      Since a side effect of the application of corticosteroids is skin atrophy, additionally three
      non-lesional test areas (not affected by psoriasis) on the volar forearm will be treated with
      the active reference product, one of the fixed combinations and the vehicle. Skin atrophy
      will be investigated by visual assessment and ultrasound at these test areas
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">May 2014</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the curve, AUC, of the width of the echo-lucent band based on sonography measurements</measure>
    <time_frame>day 1 vs day 29</time_frame>
    <description>The primary objective is to gain evidence suggesting efficacy of the investigational products in the treatment of plaque-type psoriasis as assessed by the AUC of the width of the echo-lucent band</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>erythema and induration</measure>
    <time_frame>day 1 vs day 29</time_frame>
    <description>investigation of the individual scores for erythema and induration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>local skin tolerability</measure>
    <time_frame>every day for 28 days</time_frame>
    <description>Safety investigation of tolerability parameters assessed by a dermatologist</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>atrophy</measure>
    <time_frame>day1 vs day 29</time_frame>
    <description>investigation of skin atrophy assessments on non-lesional test areas</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>assessment of (serious) Adverse Events</measure>
    <time_frame>from baseline to day 29</time_frame>
    <description>Daily record will be performed and - if needed - causality and severity assessed</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>formulation 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>topical treatment, once daily for 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>formulation 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>topical treatment, once daily for 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>formulation 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>topical treatment, once daily for 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>formulation 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>topical treatment,once daily for 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>formulation 5</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>topical treatment, once daily for 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>formulation 6</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>topical treatment, once daily for 4 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LAS41004-IMP1</intervention_name>
    <description>daily topical application</description>
    <arm_group_label>formulation 1</arm_group_label>
    <arm_group_label>formulation 2</arm_group_label>
    <arm_group_label>formulation 3</arm_group_label>
    <arm_group_label>formulation 4</arm_group_label>
    <arm_group_label>formulation 5</arm_group_label>
    <arm_group_label>formulation 6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LAS41004 IMP2</intervention_name>
    <description>daily topical application</description>
    <arm_group_label>formulation 1</arm_group_label>
    <arm_group_label>formulation 2</arm_group_label>
    <arm_group_label>formulation 3</arm_group_label>
    <arm_group_label>formulation 4</arm_group_label>
    <arm_group_label>formulation 5</arm_group_label>
    <arm_group_label>formulation 6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LAS41004 IMP3</intervention_name>
    <description>daily topical application</description>
    <arm_group_label>formulation 1</arm_group_label>
    <arm_group_label>formulation 2</arm_group_label>
    <arm_group_label>formulation 3</arm_group_label>
    <arm_group_label>formulation 4</arm_group_label>
    <arm_group_label>formulation 5</arm_group_label>
    <arm_group_label>formulation 6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LAS41004 IMP4</intervention_name>
    <description>daily topical application</description>
    <arm_group_label>formulation 1</arm_group_label>
    <arm_group_label>formulation 2</arm_group_label>
    <arm_group_label>formulation 3</arm_group_label>
    <arm_group_label>formulation 4</arm_group_label>
    <arm_group_label>formulation 5</arm_group_label>
    <arm_group_label>formulation 6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LAS41004 IMP6</intervention_name>
    <description>daily topical application</description>
    <arm_group_label>formulation 1</arm_group_label>
    <arm_group_label>formulation 2</arm_group_label>
    <arm_group_label>formulation 3</arm_group_label>
    <arm_group_label>formulation 4</arm_group_label>
    <arm_group_label>formulation 5</arm_group_label>
    <arm_group_label>formulation 6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LAS41004 IMP5</intervention_name>
    <description>once daily, topical</description>
    <arm_group_label>formulation 1</arm_group_label>
    <arm_group_label>formulation 2</arm_group_label>
    <arm_group_label>formulation 3</arm_group_label>
    <arm_group_label>formulation 4</arm_group_label>
    <arm_group_label>formulation 5</arm_group_label>
    <arm_group_label>formulation 6</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria:

          -  18 to 75 years of age

          -  Men and women with skin type I to IV (Fitzpatrick 1974).

          -  Suffering from mild to moderate plaque psoriasis of at least 6 months duration that is
             amenable to local therapy.

          -  With at least one stable psoriatic plaque in an area sufficient for product
             application meeting the following criteria:

               -  Located at the trunk and/or the extremities (plaques located on the head, palms,
                  or soles of the feet, intertriginous or genitoanal areas are not suitable).

               -  Plaques with a clinical score of the parameter erythema and or induration of ≥ 2
                  for each sign at the screening visit. At Day 1 each parameter has to be scored ≥
                  2.

               -  Where more than one plaque is to be used, plaques should be comparable, with at
                  least &quot;2&quot; in each score for erythema and induration.

               -  • Body surface area (BSA) involvement &lt; 10 %.

          -  Prepared to give written informed consent specific to the trial, before any assessment
             is performed.

          -  • In the case of women of childbearing potential using reliable methods of
             contraception which result in a low failure rate i.e. less than 1% per year (e.g.
             contraceptive implants or injectables, combined oral contraceptives, some intrauterine
             devices, sexual abstinence or vasectomized partner). During the study an additional
             barrier method (e.g. condoms) should be used. Non-childbearing potential is defined as
             surgical sterilization (hysterectomy, ovariectomy or tubal ligation), postmenopausal
             status (continuous amenorrhea of at least 2 years).

          -  In the case of men with partners of childbearing potential willingness of using
             condoms during the study conduct and 1 month after end of treatment.

        Main Exclusion Criteria:

          -  • Patients who need systemic treatment for their psoriasis.

               -  Severe forms of psoriasis or forms of psoriasis other than chronic plaque
                  psoriasis,

               -  Systemic treatment (see table below):

        Corticosteroids, antibiotics 4 weeks prior to trial Day 1 and during conduct of trial
        Retinoids Ciclosporin Methotrexate Fumaric acid esters 3 months prior to trial Day 1 and
        during conduct of trial Anti-inflammatory substances, NSAIDs 2 weeks prior to trial Day 1
        and during conduct of trial Biologics 6 months prior to trial Day 1 and during conduct of
        trial

          -  Topical treatment of all other body regions with corticosteroids or immunosuppressants
             where more than 20 % of the body surface area is treated.

          -  Diseases:

        Significant skin infections caused by bacteria, viruses or fungi, including but not limited
        to tuberculosis, syphilis or varicella zoster infection Parasitic infections
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kirstin Deuble-Bente, Dr med</last_name>
    <role>Principal Investigator</role>
    <affiliation>proDERM GmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>proDERM GmbH</name>
      <address>
        <city>Schenefeld</city>
        <state>Schleswig-Holstein</state>
        <zip>22869</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 24, 2014</study_first_submitted>
  <study_first_submitted_qc>April 10, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 11, 2014</study_first_posted>
  <last_update_submitted>June 6, 2014</last_update_submitted>
  <last_update_submitted_qc>June 6, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 9, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>psoriasis plaque test</keyword>
  <keyword>topical application</keyword>
  <keyword>atrophy measure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

